{Reference Type}: Case Reports
{Title}: Sirolimus combined with glucocorticoids in the treatment of Kasabach-Merritt phenomenon in a neonate: A case report.
{Author}: Cheng J;Zou Y;Fu R;Jin P;Huang M;Wu Z;Bai H;Huang X;Yuan H;
{Journal}: Medicine (Baltimore)
{Volume}: 103
{Issue}: 14
{Year}: 2024 Apr 5
{Factor}: 1.817
{DOI}: 10.1097/MD.0000000000037706
{Abstract}: BACKGROUND: Kaposiform hemangioendothelioma is an aggressive vascular tumor that is often associated with life-threatening coagulopathies and Kasabach-Merritt phenomenon. Pathologic biopsies can provide a good basis for diagnosis and treatment. Therapy with srolimus combined with glucocorticoids may offer patients a favorable prognosis.
METHODS: A large purplish-red mass on the knee of a child with extremely progressive thrombocytopenia and refractory coagulation abnormalities. Conventional doses of glucocorticoids alone failed to improve coagulation abnormalities and the child developed large cutaneous petechiae and scalp hematomas.
METHODS: Kaposiform hemangioendothelioma combined with Kasabach-Merritt phenomenon.
METHODS: The patient received prednisolone 2.0 mg/kg*d for 4 days. Blood products were transfused to ensure vital signs and to complete the pathologic biopsy. Sirolimus combined with prednisolone was given after clarifying the diagnosis of Kaposiform hemangioendothelioma.
RESULTS: The tumor basically disappeared on examination and the ultrasound showed a subcutaneous hyperechoic mass with normal blood flow.
CONCLUSIONS: Sirolimus combined with glucocorticoids is effective in controlling Kasabach-Merritt phenomenon and pathologic biopsy is important for definitive diagnosis.